<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03573999</url>
  </required_header>
  <id_info>
    <org_study_id>OsmoMetOx</org_study_id>
    <nct_id>NCT03573999</nct_id>
  </id_info>
  <brief_title>Effect of Mannitol 20% Versus Hypertonic Saline 7.5% in Brain Metabolism and Oxygenation</brief_title>
  <official_title>Effect of Isosmotic Doses of Mannitol 20% Versus Hypertonic Saline 7.5% in Brain Metabolism and Oxygenation in Supratentorial Craniotomies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aristotle University Of Thessaloniki</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Usage of osmotic agents is a standard practice in neuroanesthesia since cerebral edema is a&#xD;
      very common situation for patients with pathology in the brain. Cerebral edema is defined as&#xD;
      the accumulation of fluid in the intracellular or extracellular compartments of the brain.&#xD;
      Among other situations that have nothing to do with the brain, a supratentorial pathology&#xD;
      such as a tumor, traumatic injury or an aneurysm, will lead to disruption of blood-brain&#xD;
      barrier, and energy crisis of the cells that will cause mainly vasogenic and cytotoxic&#xD;
      cerebral edema. The most common monitoring method for &quot;measuring&quot; cerebral edema is ICP&#xD;
      (intracranial pressure) in which normal values are (with differences in the bibliography)&#xD;
      10-15 mmHg.&#xD;
&#xD;
      The osmotic agents used most in neuroanesthesia are mannitol 20% and hypertonic NaCl 7.5% or&#xD;
      3%. Their brain relaxation effectiveness is supposed to be quite the same between the two&#xD;
      different agents. Their main difference is that mannitol induces diuresis. Also, electrolyte&#xD;
      disorders are another possibility after mannitol infusion. On the other hand, NaCl 7.5%&#xD;
      causes vasodilation, does not induce diuresis and hemodynamically, even though it reduces&#xD;
      SBP, it raises CO because of its excessive vasodilation. But both reduce cerebral edema due&#xD;
      to the change of osmotic pressure in the vessels, that leads to extracting water from brain&#xD;
      cells.&#xD;
&#xD;
      A supratentorial craniotomy is de facto worsening the oxygenation and metabolism condition of&#xD;
      the surgical site, adding to the problem the intracranial pathology causes in the first&#xD;
      place. So if oxygen provided is low and the metabolic rate is high, the rate of anaerobic&#xD;
      metabolism will raise. Measuring the oxygen in the jugular bulb is the most reliable&#xD;
      monitoring method of cerebral oxygenation and metabolism.&#xD;
&#xD;
      It becomes evident that optimization of cerebral oxygenation during a craniotomy will&#xD;
      possibly affect the outcome of a patient, by improving it. So, if any superiority of one&#xD;
      osmotic agent over the other could be demonstrated this will be very helpful in the decision&#xD;
      making in routine clinical practice.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each participant will receive standard monitoring (ECG, SpO2, SBP, BIS, urine output,&#xD;
      temperature). More detailed hemodynamic monitoring will be obtained by Edwards Lifesciences&#xD;
      ClearSight system (CO, CI, SV, SVI, SVV, SVR, SVRI).&#xD;
&#xD;
      TCI Propofol and Remifentanil will be the agents of choice for induction and maintenance in&#xD;
      anesthesia and cisatracurium will be used for neuromuscular blockade for intubation.&#xD;
&#xD;
      Protective mechanical ventilation will be chosen (7ml/kg IBW) with a Respiratory rate to&#xD;
      obtain a PaCO2 of 35-40 mmHg. PEEP will be changed for the best PaO2/FiO2 ratio and FiO2 of&#xD;
      choice will be 0.5.&#xD;
&#xD;
      The radial artery catheterization will be applied for direct blood pressure measurement and&#xD;
      arterial blood gas sampling ( pH, PaO2, PaCO2, HCO3, BE, Osmolality, Lactic acid, Hb,&#xD;
      Glucose, Na, K will be measured).&#xD;
&#xD;
      The jugular bulb ipsilateral to the craniotomy site will be catheterized for receiving blood&#xD;
      samples for blood gas analysis. The following oxygenation and metabolic parameters /&#xD;
      derivates will be measured or calculated: SjvO2, pH, PjvO2, PjvCO2, HCO3, BE, Osmolality,&#xD;
      Lactic acid jv, Hb, Glucose, Na, K, AjvDO2, AjvCO2, O2ERbr, eRQbr, AjvDL, and LOI.&#xD;
&#xD;
      The osmotic agent will be administered 20 minutes before dura matter incision. Before the&#xD;
      dura mater opening the subdural space pressure will be measured and relevant CPP will be&#xD;
      calculated. Brain Relaxation Score will be assessed by the neurosurgeon.&#xD;
&#xD;
      Phases&#xD;
&#xD;
        -  T0: 5 minutes before administration of the osmotic agent&#xD;
&#xD;
        -  T15: 15 minutes after administration of the osmotic agent&#xD;
&#xD;
        -  T30: 30 minutes after administration of the osmotic agent&#xD;
&#xD;
        -  T60: 60 minutes after administration of the osmotic agent&#xD;
&#xD;
        -  T90: 90 minutes after administration of the osmotic agent&#xD;
&#xD;
        -  T120: 120 minutes after administration of the osmotic agent&#xD;
&#xD;
        -  T180: 180 minutes after administration of the osmotic agent&#xD;
&#xD;
        -  T240: 240 minutes after administration of the osmotic agent Blood samples for measuring&#xD;
           S-100b will be collected at phases T0, T240 and 12 hours after osmotic agent&#xD;
           administration.&#xD;
&#xD;
      Postoperative complications, length of ICU stay, GOS-E (Glasgow Outcome Scale) and other&#xD;
      neurological deficits will be recorded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 29, 2018</start_date>
  <completion_date type="Actual">December 20, 2019</completion_date>
  <primary_completion_date type="Actual">October 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of jugular venous oxygen saturation</measure>
    <time_frame>15 minutes after the end of the infusion of the tested osmotic agent</time_frame>
    <description>Alterations in jugular venous oxygen saturation (%) after intravenous infusion of isosmotic doses of mannitol 20% and hypertonic saline 7.5%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes of S-100b protein</measure>
    <time_frame>6 hours after the end of the infusion of the tested osmotic agent</time_frame>
    <description>Alterations in S-100b (μg/L) after intravenous infusion of isosmotic doses of mannitol 20% and hypertonic saline 7.5%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the cardiac index</measure>
    <time_frame>15 minutes after the end of the infusion of the tested osmotic agent</time_frame>
    <description>Alterations in the cardiac index (L/min/m2) after intravenous infusion of isosmotic doses of mannitol 20% and hypertonic saline 7.5%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brain tension after intravenous infusion of isosmotic doses of mannitol 20% and hypertonic saline 7.5% assessed by Brain relaxation Score and subdural pressure</measure>
    <time_frame>2 minutes before dura opening</time_frame>
    <description>Brain tension graded from 1 to 4 (1 indicates satisfactory brain relaxation and 4 serious brain bulking)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcome of participants</measure>
    <time_frame>7 days post surgery</time_frame>
    <description>Functional status of the participants assessed by Extended GOS ranginging from 1 to 7 (1 indicates death and 7 neurologically intact patient)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Brain Edema</condition>
  <condition>Metabolic Disturbance</condition>
  <condition>Electrolyte and Fluid Balance Conditions</condition>
  <arm_group>
    <arm_group_label>Mannitol 20%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mannitol 20% (4.6ml/kg) will be administered 20 minutes before dura matter opening.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypertonic saline 7.5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypertonic saline 7.5% (2ml/kg) will be administered 20 minutes before dura matter opening</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mannitol</intervention_name>
    <description>4.6 ml/kg will be administered before dura opening</description>
    <arm_group_label>Mannitol 20%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NaCl 7.5%</intervention_name>
    <description>2 ml/kg will be administered before dura opening</description>
    <arm_group_label>Hypertonic saline 7.5%</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients aged between 18 and 75 years&#xD;
&#xD;
          -  ASA Physical status 1 to 3&#xD;
&#xD;
          -  Elective or semi-elective supratentorial craniotomy&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Craniotomy for suprasellar pathologies&#xD;
&#xD;
          -  Re-craniotomy at the same site&#xD;
&#xD;
          -  Perioperative sodium disorders (Na &lt;130 mEq/L or &gt;150 mEq/L)&#xD;
&#xD;
          -  Administration of intravenous mannitol or hypertonic saline 7.5% 24 hours or less&#xD;
             before the surgery&#xD;
&#xD;
          -  Preoperative obstructive hydrocephalus&#xD;
&#xD;
          -  Congestive heart failure&#xD;
&#xD;
          -  Renal failure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Georgia Tsaousi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aristotle University Of Thessaloniki</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AHEPA University Hospital</name>
      <address>
        <city>Thessaloníki</city>
        <zip>56224</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Tsaousi</name>
      <address>
        <city>Thessaloníki</city>
        <zip>56346</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 20, 2018</study_first_submitted>
  <study_first_submitted_qc>June 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2018</study_first_posted>
  <last_update_submitted>May 5, 2021</last_update_submitted>
  <last_update_submitted_qc>May 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aristotle University Of Thessaloniki</investigator_affiliation>
    <investigator_full_name>Georgia Tsaousi</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>mannitol</keyword>
  <keyword>hypertonic saline</keyword>
  <keyword>brain metabolism</keyword>
  <keyword>brain oxygenation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mannitol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

